NewLink Genetics Corporation
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | NewLink Genetics Corporation |
Stock Symbol : | NASDAQ:NLNK |
Class Period Start: | 09/17/2013 |
Class Period End: | 05/09/2016 |
Lead Plaintiff motion: | 07/11/2016 |
Date Filed: | 05/12/2016 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Southern District of New York |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the July 11, 2016 lead plaintiff deadline in a class action lawsuit filed against NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased NewLink Genetics Corporation securities between September 17, 2013 and May 9, 2016, have until July 11, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased NewLink Genetics Corporation securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that NewLink’s algenpantucel-L treatment was ineffective and potentially harmful to patients; and as a result of the foregoing, the Company's public statements were materially false and misleading at all relevant times. On May 9, 2016, NewLink disclosed that the Company's experimental pancreatic cancer immunotherapy algenpantucel-L failed to satisfy the main purpose of a late-stage study. Patients treated with algenpantucel-L lived for a median of 27.3 months in NewLink's phase Phase 3 Clinical Trial, compared to median survival of 30.4 months for patients treated with standard therapy, suggesting that patients were actually harmed by algenpantucel-L. On this news, NewLink shares dropped over 30% on May 10, 2016. If you were negatively impacted by your investment in NewLink Genetics Corporation securities between September 17, 2013 and May 9, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |